FindTrial
Sign In

AZD9668

DRUG11 trials

Sponsors

AstraZeneca, Nick Giannoukakis, PhD

Conditions

BronchiectasisChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Cystic FibrosisHealthyInsulin ResistancePharmacodynamicsPharmacokinetics

Phase 1

AZD9668 Relative Bioavailability
CompletedNCT01034982
AstraZenecaChronic Obstructive Pulmonary Disease
Start: 2009-11-30End: 2009-12-31Updated: 2010-02-05
AZD9668 Relative Bioavailability
CompletedNCT01035411
AstraZenecaChronic Obstructive Pulmonary Disease
Start: 2009-11-30End: 2009-12-31Updated: 2013-01-29
Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject
CompletedNCT01161355
AstraZenecaHealthy
Start: 2010-06-30End: 2010-06-30Updated: 2011-02-09
A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin
WithdrawnNCT01214122
AstraZenecaPharmacodynamics, Pharmacokinetics
Start: 2010-11-30End: 2010-12-31Updated: 2013-01-29

Phase 2

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
CompletedNCT00703391
AstraZenecaChronic Obstructive Pulmonary Disease (COPD)
Start: 2008-06-30End: 2008-09-30Updated: 2012-01-26
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
CompletedNCT00757848
AstraZenecaCystic Fibrosis
Start: 2008-10-31End: 2009-08-31Updated: 2012-08-20
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
CompletedNCT00769119
AstraZenecaBronchiectasis
Start: 2008-09-30End: 2009-04-30Updated: 2012-08-20
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
CompletedNCT00949975
AstraZenecaChronic Obstructive Pulmonary Disease
Start: 2009-07-31End: 2010-08-31Updated: 2012-08-03
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
CompletedNCT01023516
AstraZenecaChronic Obstructive Pulmonary Disease (COPD)
Start: 2009-11-30End: 2010-08-31Updated: 2012-08-03
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
CompletedNCT01054170
AstraZenecaChronic Obstructive Pulmonary Disease (COPD)
Start: 2010-01-31End: 2010-11-30Updated: 2012-08-20
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
CompletedNCT02597101
Nick Giannoukakis, PhDInsulin Resistance, Type 2 Diabetes Mellitus
Start: 2015-11-30End: 2019-06-15Updated: 2021-05-13

Related Papers

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials.
2014-10-0784 citations
Performance of the EXAcerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in Three Clinical Trials of Chronic Obstructive Pulmonary Disease
Annals of the American Thoracic Society2014-02-1455 citations
Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
2013-02-20155 citations
A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
2012-04-0173 citations
AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
2011-12-2371 citations